Close menu




April 9th, 2022 | 07:27 CEST

BioNTech, Triumph Gold, Rheinmetall - Uncertainties everywhere

  • Gold
  • Inflation
Photo credits: pixabay.com

The ongoing fighting in Ukraine and concerns about an escalation of the situation are worrying capital markets worldwide. Nevertheless, the leading stock market barometers were able to distance themselves significantly from their lows. Now, the next blow has followed with the publication of the FED's meeting minutes. The US Federal Reserve wants to accelerate the reduction of its balance sheet total and let bonds worth up to USD 95 billion expire without buying again. In doing so, the monetary authorities are hitting technology stocks in particular, which have already been in a sharp correction since the beginning of the year. Gold, on the other hand, is barely reacting despite the expected interest rate hikes, a strong sign for the precious metal.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , TRIUMPH GOLD CORP. | CA8968121043 , RHEINMETALL AG | DE0007030009

Table of contents:


    Inflation keeps the stock markets in suspense

    A decision will be made at the beginning of May as to whether the Federal Reserve will massively reduce the size of its balance sheet. Due to the high inflation, which amounted to 7.9% in the USA in March, a tightening of monetary policy is more than overdue. Per month, bonds worth up to USD 95 billion will expire without buying new ones, according to the FED minutes published yesterday evening. After the key interest rate was already raised by 0.25% at the meeting on March 16, several steps are likely to be taken this year due to the continued high inflation rate. In addition, the Ukraine crisis is expected to fuel inflation further due to rising commodity and energy prices. The question is whether the central bankers will still manage to contain inflation or whether inflation rates have already gotten out of hand. Already last year, we were very skeptical of the statements of the monetary guardians that inflation was only temporary in nature.

    Gold is still "the" inflation hedge

    Admittedly, one would have expected higher prices for gold already last year due to the general conditions with low interest rates, high inflation rates and uncertainties in geopolitics. Even after Russia's invasion, the gold price briefly scratched the all-time high of USD 2,070.18 per ounce, only to be sold off again. Gold has become the plaything of the political powers; a high fluctuation range can therefore not be ruled out. However, should the price correct even in the short term towards the uptrend at USD 1,680 per ounce, it should achieve significantly higher prices in the medium term.

    So, in addition to buying physical gold in the form of coins or bars, shares in gold producers or exploration companies such as Triumph Gold make sense to protect one's assets from the threat of devaluation. The formula for portfolio diversification is to invest about 10% in gold or silver stocks. The Canadian company, listed in Frankfurt and Toronto, has consolidated around 70% since the all-time high of the base price in August 2020 and has been working on bottoming out at CAD 0.10 for months.

    The Canadians' focus is on developing the Freegold Mountain project in Canada's Yukon using multi-disciplinary exploration and evaluation technologies. The 100% owned project is equipped with world-class infrastructure and hosts three National Instrument 43-101 compliant mineral deposits, Nucleus, Revenue and Tinta Hill. In addition, the exploration company owns 100% of the Big Creek and Tad/Toro copper-gold properties near the Freegold Mountain project.

    The Canadians reported good results from the 755.90m drill program in two holes at the Nucleus deposit at the Freegold Mountain project. Highlights include 4.50m at 2.00 g/t gold and 1.57 g/t silver within 46.28m at 0.54 g/t gold and 0.53 g/t silver in N21-02 in the Oxide Zone, which returned a gold recovery rate of 83%. Brian May, Triumph Gold's CEO, is extremely positive about the results and expects to define additional oxide gold zones in the future. Triumph Gold's market capitalization is approximately EUR 9.69 million.

    Correction of the crisis profiteers

    Be it Corona or the current Ukraine crisis. Besides many losers, led by our society, there are, of course, also winners. While at the time of the virus, it was mainly the vaccine producers around BioNTech, Pfizer & Co. that were the winners, the increase in the budget for the German armed forces is driving Rheinmetall investors to jump for joy. But caution is advised. BioNTech was able to recover somewhat in recent days after the slide. However, the stock did not have the strength to close the price gap at USD 194.61 and turned south again. Important now is the upward trend formed since September at USD 160.47. Should this fall, a further sell-off to the next prominent support area at USD 131.00 would be possible.

    In the case of the Rheinmetall defense share, a strong sell-off occurred after a new high of EUR 209.70 was reached; in addition, the trend-following indicators turned downward and showed a sell signal. In the short term, the correction potential is initially EUR 180.


    The markets remain depressed and turned down again due to the FED meeting minutes. As diversification, an investment in gold mining stocks such as Triumph Gold offers itself in the long term. Extreme caution is advised with the crisis winners BioNTech and Rheinmetall.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Jens Castner on October 30th, 2026 | 05:45 CET

    When the stock market gets it wrong: Schott Pharma clears its name; Lahontan Gold and Instone are the next candidates

    • Speciality glass
    • Gold
    • Real estate
    • Chemicals
    • Silver
    • Expropriation
    • Health
    • Berlin
    • Misvaluations
    • Mining
    • Schott Pharma
    • Instone Real Estate
    • Lahontan Gold

    Markets are quick to judge, and often paint companies with a broad brush. When one company runs into difficulties, its competitors immediately come under suspicion too. Schott Pharma has already been through this and dispelled the doubts with strong figures. Its share price is recovering. For Lahontan Gold and Instone Real Estate, the recovery has yet to come. The Canadian gold explorer is being punished alongside the major producers, while the property developer is being grouped with Berlin's residential landlords. In both cases, the facts tell a different story. The share price upside is considerable.

    Read

    Commented by Jens Castner on October 29th, 2026 | 05:40 CET

    A Breakout in the Making? Desert Gold Ventures and Oklo following in Moderna's footsteps

    • Cancer therapy
    • Gold
    • Nuclear power
    • Biotech
    • Commodities
    • Data centres
    • Desert Gold
    • Moderna
    • Oklo
    • Analysts
    • Price targets
    • Milestones
    • Quarterly reports
    • Precious metal

    Created and published on behalf of Desert Gold Ventures.

    Moderna has already made the big leap. Yet the best trial data in the company's history sent the shares tumbling, because the success was already priced in. The situation is different for two stocks that have also reached crucial milestones but still attract little attention on the stock market. Desert Gold Ventures is on the verge of its first gold production in Mali. Nuclear power specialist Oklo has commissioned its first reactor, but still needs a little more time before its commercial breakthrough. Analysts' price targets for both shares are several times their current prices.

    Read

    Commented by Carsten Mainitz on October 29th, 2026 | 05:31 CET

    Gold, Tickets, Turnarounds! Why Stock Pickers Should Take a Closer Look at DRC Gold, CTS Eventim and Mutares Now

    • Stock Picking
    • Alpha
    • Investments
    • Gold
    • Exploration
    • Acquisition
    • Activist Investor

    The stock market is no petting zoo. Investors seeking returns have to go hunting themselves. Stock picking is the art of finding tomorrow's winners before the rest of the market wakes up. Under the leadership of industry veteran Klaus Eckhof, DRC Gold is working to take a stake in a gold project in the northeast of the Democratic Republic of the Congo. This could take the company to a whole new level. CTS Eventim is attracting renewed attention thanks to an activist investor. This could boost the share price. Mutares has many irons in the fire. Who is ahead?

    Read